Tysabri For Crohn’s: Risk Management Is Same, But Could Be Higher Hurdle
Executive Summary
The approval of Biogen Idec/Elan's multiple sclerosis treatment Tysabri (natalizumab) for Crohn's disease will expand the use of the product's multi-layered risk management program
You may also be interested in...
Internet Searching May Get ‘Riskier’ For Patients After FDA Citations
“Sponsored searches” need to contain risk information, agency tells 14 firms in letters covering 48 products.
Biogen, Amylin Feel Impact Of Safety Scares; Another Wrinkle With TOUCH
Biogen Idec's landmark risk management program for Tysabri (natalizumab) is paying another dividend for the company: providing management with a credible source of data to reassure investors nervous about the commercial impact of newly reported cases of progressive multifocal leukoencephalopathy (PML) associated with the MS therapy
Biogen, Amylin Feel Impact Of Safety Scares; Another Wrinkle With TOUCH
Biogen Idec's landmark risk management program for Tysabri (natalizumab) is paying another dividend for the company: providing management with a credible source of data to reassure investors nervous about the commercial impact of newly reported cases of progressive multifocal leukoencephalopathy (PML) associated with the MS therapy